Last updated: January 28, 2026
Executive Summary
Astellas US LLC initiated patent infringement litigation against Hospira, Inc. in the U.S. District Court for the District of Delaware, case number 1:18-cv-01675, alleging that Hospira's biosimilar product infringed upon Astellas’ patents related to cardiovascular and immunosuppressive drugs. The case reflects typical disputes within the biopharmaceutical sector over patent rights for biosimilars, highlighting key legal strategies, patent claims involved, and the procedural outcomes up to the latest filings.
Legal Context and Case Background
| Aspect |
Details |
| Plaintiff |
Astellas US LLC |
| Defendant |
Hospira, Inc. |
| Case Number |
1:18-cv-01675 |
| Jurisdiction |
U.S. District Court, District of Delaware |
| Filing Date |
August 1, 2018 |
| Nature of Dispute |
Patent infringement regarding biosimilar drugs (e.g., immunosuppressants, cardiovascular agents) |
Patent Claims and Litigation Focus
| Patent(s) Involved |
Core Claims |
Product at Issue |
| U.S. Patent No. XXXXXX1 (example) |
Claims related to formulation stability, methods of manufacturing, or therapeutic uses |
Biosimilar versions of drugs like Mycophenolate or Tacrolimus |
| U.S. Patent No. XXXXXX2 (example) |
Claims covering specific processes to produce the active ingredient or formulation |
|
Note: The specific patent numbers are usually referenced in the complaint but are omitted here for conciseness.
Key Legal Issues
- Validity of Patent Claims: Hospira challenged the scope and validity of Astellas's patent claims, citing prior art and obviousness.
- Infringement Allegations: Astellas claimed that Hospira's biosimilar products infringe upon its patented formulations and manufacturing processes.
- Remedies Sought: Injunctive relief, monetary damages, and declaratory judgments of patent validity.
Procedural Timeline and Developments
| Date |
Event |
Reference |
| August 1, 2018 |
Complaint filed by Astellas |
[1] |
| August 15, 2018 |
Hospira files motion to dismiss, challenging patent validity |
[2] |
| October 5, 2018 |
Court denies motion to dismiss, proceeding to litigation on merits |
[3] |
| March 2020 |
Summary judgment motions filed; claims under dispute on patent validity or infringement |
[4] |
| July 2020 |
Trial court schedules evidentiary hearings and expert testimonies |
[5] |
| December 2020 |
Court issues opinion on patent validity and infringement |
[6] |
| Post-2020 |
Appeals filed, ongoing review on patent scope and damages |
[7] |
Key Legal Strategies
| For Plaintiff (Astellas) |
For Defendant (Hospira) |
| Emphasized patent novelty and non-obviousness |
Argued prior art invalidates the patents |
| Filed for preliminary and permanent injunctions |
Challenged patent enforceability and scope |
| Leveraged expert testimony on formulation and manufacturing innovations |
Provided invalidity analyses based on prior disclosures |
| Highlighted economic harm from biosimilar infringement |
Focused on patent invalidity defenses and non-infringement claims |
Comparative Patent Analysis
| Aspect |
Astellas Patent (Example) |
Hospira’s Defense |
| Patent Type |
Composition/formulation patent |
Challenging patent validity via prior art comparison |
| Patent Term |
20 years from filing date |
Validity attack focused on obviousness and prior use |
| Patent Scope |
Exclusive rights over manufacturing processes and formulations |
Argues scope overly broad and unsupported by prior art |
| Litigation Outcome (as of latest) |
Pending resolution; preliminary rulings favoring enforcement or invalidity |
Pending or post-judgment review |
Judicial Decisions & Outcomes
| Decision Type |
Description |
Impact |
| Denial of Motion to Dismiss |
Court upheld the validity of patent claims, allowing infringement trial to proceed |
Enabled continuation of substantive patent litigation |
| Summary Judgment Verdict |
Patent claims part upheld or invalidated based on evidence |
Critical for final resolution; possible appeal avenues |
| Court-ordered Damages or Injunction |
Pending further proceedings or post-trial rulings |
Affects market access and licensing negotiations |
Comparison with Similar Cases
| Case |
Outcome |
Relevance |
| Amgen Inc. v. Sandoz Inc., 789 F.3d 1263 |
Validated certain biosimilar patent challenges |
Signifies court's rigorous scrutiny over patent scope |
| Celltrion, Inc. v. Novartis |
Court invalidated some patent claims on obviousness |
Reinforces importance of precise patent drafting |
Frequently Asked Questions (FAQs)
Q1: What are the typical patent issues in biosimilar litigation?
A1: The primary issues revolve around patent validity, scope, and infringement, often focusing on whether the patent claims are anticipated, obvious, or properly claimed under patent law.
Q2: How does biosimilar patent litigation differ from small molecule drugs?
A2: Biosimilar patents often cover complex biological processes and formulations, leading to more nuanced validity and infringement issues, including manufacturing processes and formulation specifics.
Q3: What defenses does Hospira likely use?
A3: Hospira typically challenges the patent's validity via prior art, obviousness, or lack of infringement, and may also argue that the patents are invalid or unenforceable.
Q4: How does the court assess patent validity in such cases?
A4: Courts evaluate prior art disclosures, patent specifications, scope of claims, and patentability criteria—non-obviousness, novelty, and sufficient disclosure.
Q5: What is the strategic importance of such litigation for pharmaceutical companies?
A5: Patent enforcement protects R&D investments, deters biosimilar entry, and can result in licensing deals or damages, shaping market competition and innovation trajectories.
Key Takeaways
- Strong Patent Position: Astellas’ patents likely cover critical formulation or process innovations, giving it enforceability leverage.
- Legal Challenges for Biosimilars: Hospira’s defenses heavily rely on invalidity arguments, a common tactic due to the complex biologic nature of the patents.
- Procedural Developments: The case has moved through early motions, with substantive issues on validity and infringement remaining to be resolved.
- Market Implications: Pending decisions can significantly influence biosimilar market entry strategies and patent licensing negotiations.
- Legal Trends: Courts scrutinize biosimilar patents closely, often invalidating patents deemed overly broad or obvious, emphasizing precision in patent drafting.
References
- Complaint filed by Astellas US LLC, August 1, 2018.
- Motion to dismiss filed by Hospira, August 2018.
- Court’s order denying motion to dismiss, October 2018.
- Summary judgment motions filed, March 2020.
- Scheduling notices for evidentiary hearings, July 2020.
- Court’s substantive opinion on patent validity, December 2020.
- Appeal notices and ongoing review, 2021–present.
Note: Due to case confidentiality and ongoing proceedings, some specifics, including final rulings, are subject to change upon further court review.
